Third Harmonic Bio (THRD) shares slumped 25% in recent Tuesday trading after the company announced a 50% workforce cut, a strategic review, including potential transactions or business combinations, and a halt in all research unrelated to its THB335 drug candidate for chronic spontaneous urticaria.
THB335 phase 1 data support advancement into a phase 2 clinical trial, the company said Tuesday in a statement. Full results will be presented at a medical conference in March.
The phase 2 trial is expected to start by mid-2025.
Third Harmonic had $285 million in cash and cash equivalents as of Dec. 31.
Price: 3.51, Change: -1.15, Percent Change: -24.62
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。